2026年3月3日周二,Compass Pathways (NASDAQ:CMPS)在TD Cowen第46届年度医疗保健会议上发表演讲,公布了其治疗难治性抑郁症 (TRD)药物COMP360的III期临床试验令人鼓舞的结果。该公司在强调该药物疗效的同时,特别是25mg剂量的疗效,也讨论了监管审批和商业化策略方面的挑战。

伦敦和纽约 - Compass Pathways plc (NASDAQ:CMPS) 通过行权2025年1月13日发行的35,059,448份权证筹集了约2亿美元资金,该公司在新闻稿中表示。 这家生物技术公司正在向特定机构投资者发行15,160,619份美国存托股份,以及可购买至多19,898,829份美国存托股份的预付费权证以代替美国存托股份。 Compass ...

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 ...